Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Sporozoite surface protein P52 (PfP52) is a member of the 6-Cys (s48/45) protein family in the malaria parasite Plasmodium falciparum. It is primarily expressed on the surface of sporozoites, the stage of the parasite transmitted by mosquitoes to humans. P52 functions in a critical complex with the protein P36 to facilitate the formation of the parasitophorous vacuole (PV) within host hepatocytes. Without functional P52, the parasite can invade the liver cell but fails to establish the PV, leading to an immediate arrest in development. This essential role makes P52 a primary target for the development of genetically attenuated parasite (GAP) vaccines, such as the PfSPZ-GA1 candidate. In these vaccines, the p52 gene is deleted to create a live-attenuated parasite that can stimulate a robust immune response without causing disease. Additionally, P52 is a target for research into monoclonal antibodies designed to block the initial infection of the liver.
Induction of protective T-cell and antibody responses to arrest parasite development in the liver; Inhibition of hepatocyte invasion by blocking protein-receptor interactions.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sporozoite surface protein P52 (PfP52).